What symptoms should prompt a doctor to consider a CACNA1D mutation in a patient with high blood pressure?

Patients with early‑onset, resistant hypertension—especially before age 30—along with low potassium levels and a normal adrenal imaging scan may raise suspicion for a CACNA1D‑related aldosterone‑producing adenoma. Symptoms such as headaches, muscle cramps, or unexplained fatigue can also be clues. A comprehensive workup including plasma aldosterone concentration and renin activity is the first step.

Are family members at risk if a patient has a CACNA1D mutation causing an aldosterone‑producing adenoma?

Most CACNA1D mutations in aldosterone‑producing adenomas are somatic, meaning they arise only in the tumor cells and are not inherited. Therefore, family members typically do not need genetic testing for this condition. However, if a germline CACNA1D mutation is identified (rare), first‑degree relatives should be screened for hypertension and adrenal abnormalities.

What lifestyle changes can help manage hypertension associated with a CACNA1D‑related adrenal adenoma before surgery?

dopting a low‑sodium diet, maintaining a healthy weight, engaging in regular aerobic exercise, and limiting alcohol intake can help lower blood pressure. Additionally, potassium‑rich foods (bananas, leafy greens) may counteract hypokalemia. These measures can reduce symptoms and improve surgical outcomes, but they do not replace definitive treatment.

How is a CACNA1D mutation detected in adrenal tumors, and does it affect treatment choices?

Tumor tissue from an adrenalectomy is sequenced for somatic CACNA1D mutations. If a mutation is present, it indicates that the tumor’s calcium channel is overactive, leading to excess aldosterone. Knowing this can guide postoperative monitoring; patients may need more aggressive blood‑pressure management and closer follow‑up for recurrence. In some cases, targeted medical therapy (e.g., calcium‑channel blockers) may be considered, though surgery remains the definitive treatment.

CACNA1D gene

The CACNA1D gene encodes the CaV1.3 calcium‑channel subunit, a key regulator of calcium flow in many tissues and a contributor to several endocrine, neurological, and cardiac disorders.

Overview

The CACNA1D gene belongs to a family of genes that provide instructions for making calcium channels. These channels transport positively charged calcium atoms (calcium ions) across cell membranes. The CACNA1D gene provides instructions for making one part (the alpha‑1 subunit) of a calcium channel called CaV1.3. This subunit forms the hole (pore) through which calcium ions can flow.

CaV1.3 channels are found in many types of cells, although they play a particularly important role in the adrenal glands, which are small hormone‑producing glands located on top of each kidney. In the adrenal glands, the flow of calcium through CaV1.3 channels appears to help regulate the production of the hormone aldosterone, which helps control blood pressure by maintaining proper salt and fluid levels in the body. CaV1.3 channels are also found in the brain, heart, and inner ear, although their roles in these tissues are not well understood.

Health Conditions Related to Genetic Changes

Aldosterone‑producing adenoma

Mutations in the CACNA1D gene have been found to cause aldosterone‑producing adenomas, which are noncancerous (benign) tumors that form in the adrenal glands. The genetic changes involved in these tumors, called somatic mutations, are acquired during a person's lifetime and are present only in adrenal gland cells that give rise to the tumors. Such mutations in the CACNA1D gene account for approximately nine percent of cases of aldosterone‑producing adenoma.

CACNA1D gene mutations associated with this condition lead to production of CaV1.3 channels that transport calcium ions more readily than normal or do not stop when they should. It is thought that the abnormal influx of calcium ions in adrenal gland cells overactivates a process called the calcium/calmodulin pathway that increases production of a hormone called aldosterone. Aldosterone helps control blood pressure by maintaining proper salt and fluid levels in the body, and abnormally high amounts of this hormone lead to high blood pressure (hypertension) and an increased risk of heart attack and stroke. Overactivation of the calcium/calmodulin pathway in the adrenal glands also increases cell growth and division (proliferation), which promotes adenoma formation.

Other disorders

Inherited CACNA1D gene mutations have been found to cause other genetic conditions. Unlike the mutations that cause aldosterone‑producing adenomas (described above), the mutations that cause these conditions are present in essentially every cell in the body. Inherited mutations that increase the flow of calcium into cells have been identified in individuals with a condition called primary aldosteronism, seizures, and neurological abnormalities (PASNA). As in aldosterone‑producing adenomas, the increased flow of calcium in adrenal gland cells increases aldosterone production, causing primary aldosteronism. It is thought that the increased flow of calcium in nerve cells (neurons) in the brain affects their function, leading to seizures and other neurological problems. Some individuals with similar CACNA1D gene mutations also have signs and symptoms of autism spectrum disorder, which affects communication and social skills. It is unclear if these individuals have PASNA or a separate condition.

Inherited CACNA1D gene mutations that reduce the flow of calcium through CaV1.3 channels have been found in individuals with sinoatrial node dysfunction and deafness (SANDD), which is characterized by an abnormally slow and irregular heartbeat (bradycardia and arrhythmia) and hearing problems. These mutations likely impair the CaV1.3 channel's function in inner ear cells, impairing hearing, and in the cluster of cells in the heart that acts as the heart's natural pacemaker (the sinoatrial node), leading to abnormal heart rhythms.

Other Names for This Gene

CACH3
CACN4
CACNL1A2
calcium channel, neuroendocrine/brain-type, alpha 1 subunit
calcium channel, voltage-dependent, L type, alpha 1D subunit
Cav1.3
CCHL1A2
voltage-gated calcium channel alpha 1 subunit
voltage-gated calcium channel alpha subunit Cav1.3

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

Tests of CACNA1D

Scientific Articles on PubMed

PubMed

Catalog of Genes and Diseases from OMIM

CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1D SUBUNIT; CACNA1D

Gene and Variant Databases

NCBI Gene
ClinVar

References

Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013 Sep;45(9):1055-60. doi: 10.1038/ng.2716. Epub 2013 Aug 4.
Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I, Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P, Striessnig J, Bolz HJ. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat Neurosci. 2011 Jan;14(1):77-84. doi: 10.1038/nn.2694. Epub 2010 Dec 5.
Pinggera A, Mackenroth L, Rump A, Schallner J, Beleggia F, Wollnik B, Striessnig J. New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy. Hum Mol Genet. 2017 Aug 1;26(15):2923-2932. doi: 10.1093/hmg/ddx175.
Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerstrom G, Bjorklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone‑producing adenomas and primary aldosteronism. Nat Genet. 2013 Sep;45(9):1050-4. doi: 10.1038/ng.2695. Epub 2013 Aug 4.
Striessnig J, Pinggera A, Kaur G, Bock G, Tuluc P. L‑type Ca2+ channels in heart and brain. Wiley Interdiscip Rev Membr Transp Signal. 2014 Mar 1;3(2):15-38. doi: 10.1002/wmts.102.

Genomic Location

The CACNA1D gene is found on chromosome 3.